← Back to patent-cliff list
ODS-101
Tier C — Watch / tradeODS-101
Oncodesign Biotechnology SA
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RIPK2
Indications (approved)：Melanoma, Inflammatory bowel disease, 间质性膀胱炎, Ulcerative colitis
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ODS-101?
Approved indications include: Melanoma, Inflammatory bowel disease, 间质性膀胱炎, Ulcerative colitis.
When does the ODS-101 patent expire?
No public expiry year is available for ODS-101 yet; this page updates once verified.
How do I get a quote for ODS-101 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30